TICKERNERD
Menu
CNMDCNMDHealthcare · Medical Devices

CNMD Stock Forecast: CONMED Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$50
+1.18% on the day

The 7 Wall Street analysts covering CONMED Corp. hold a median 12-month price target of $45 — -10.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 15 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$1.5B
Ticker Nerd rank
95 / 100
Median analyst target
$45
Analysts covering
7
Total return, dividends reinvested
1W
+2.6%
1M
+20.7%
YTD
+24.2%
1Y
−3.9%
From 52W high
−9.3%
From 52W low
+57.0%
$32
$56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CONMED Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Issuance
94
Revisions
88
Volatility
76
Quality
74
Accruals
73
Growth
48
Momentum
44
Size
40

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (44): The shares have been drifting down relative to others.

Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$35$40$45$50$55Oct 25Jan 26Apr 26Jul 26CNMDHigh $49Median $45Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
0 Buy6 Hold1 Sell
Low $43Median $45High $49

The green dot is the last close — the median target sits −10.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 July 2026Piper SandlerReiteratesNeutral$39 → $45
30 July 2026Wells FargoMaintainsEqual-Weight$39 → $46
9 July 2026BMO CapitalInitiatesMarket Perform—
29 June 2026B of A SecuritiesDowngradeUnderperform—
18 May 2026B of A SecuritiesMaintainsNeutral—
1 May 2026Wells FargoMaintainsEqual-Weight—
30 Apr 2026JP MorganMaintainsNeutral—
17 Mar 2026Piper SandlerDowngradeNeutral—
29 Jan 2026NeedhamReiteratesHold—
29 Jan 2026Wells FargoMaintainsEqual-Weight—
8 Dec 2025B of A SecuritiesMaintainsNeutral—
6 Nov 2025JP MorganMaintainsNeutral—
6 Nov 2025Piper SandlerMaintainsOverweight—
6 Nov 2025Wells FargoMaintainsEqual-Weight—
31 July 2025Piper SandlerMaintainsOverweight—
12 June 2025NeedhamDowngradeHold—
1 May 2025JP MorganMaintainsNeutral—
1 May 2025NeedhamMaintainsBuy—
1 May 2025Wells FargoMaintainsEqual-Weight—
28 Apr 2025StifelDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CNMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

CONMED Corp. (CNMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
27.2×

Cheaper than 29% of US stocks

Price / sales
1.1×

Cheaper than 68% of US stocks

Price / book
1.5×

Cheaper than 58% of US stocks

EV / EBITDA
10.1×

Cheaper than 38% of US stocks

Growth & margins
Revenue growth (YoY)
0.3%

Higher than 28% of US stocks

Earnings growth (YoY)
7.7%

Higher than 45% of US stocks

Gross margin
57.5%

Higher than 71% of US stocks

Operating margin
14.6%

Higher than 72% of US stocks

Net margin
4.1%

Higher than 58% of US stocks

Returns & dividend
Return on equity
5.5%

Higher than 54% of US stocks

Return on assets
4.1%

Higher than 72% of US stocks

Dividend yield
1.6%

Higher than 38% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CNMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CNMDCONMED Corp.$1.5B
95
TNDMTandem Diabetes Care, Inc.$1.6B
63
ENOVEnovis Corp.$1.5B
85
INSPInspire Medical Systems, Inc.$1.6B
79
ATECAlphatec Holdings, Inc.$1.5B
78
IARTIntegra LifeSciences Holdings Corp.$1.4B
89
AORTArtivion, Inc.$1.4B
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CONMED Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNMD news & analysis

CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands

Zacks Investment Research · 30 July 2026positive

CONMED reported second-quarter earnings and revenues that surpassed analyst estimates, with expanding gross margins and strong international sales contributing to an improved earnings-per-share outlook for 2026.

Why it matters — The results indicate the company is outperforming expectations and gaining financial momentum through both margin improvement and global market strength.

CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Seeking Alpha published the transcript of CONMED Corporation's Q2 2026 earnings conference call, covering management's prepared remarks and the subsequent question-and-answer session.

Why it matters — Earnings call transcripts offer CONMED watchers direct access to management's commentary on quarterly financial performance, operational highlights, and forward-looking guidance.

CONMED Q2 Earnings Call Highlights

MarketBeat · 30 July 2026positive

CONMED reported Q2 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, excluding exited gastroenterology products, rose 6% year over year and modestly exceeded management's expectations.

Why it matters — Organic sales growth of 6% modestly exceeding expectations provides a clearer picture of core business performance for CNMD investors.

Conmed (CNMD) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 29 July 2026neutral

Conmed (CNMD) reported its earnings for the quarter ended June 2026, with the article suggesting investors compare key metrics against Wall Street estimates and prior-year results.

Why it matters — CNMD watchers would care because the quarterly earnings report provides a data point to assess the company's financial performance relative to analyst expectations and historical results.

Conmed (CNMD) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 29 July 2026positive

Conmed (CNMD) reported Q2 earnings of $1.38 per share, surpassing both the Zacks Consensus Estimate of $1.10 and the prior year's earnings of $1.15 per share.

Why it matters — The earnings beat signals that Conmed's quarterly performance exceeded analyst expectations and improved from the same period last year.

FAQ

Frequently asked questions about CNMD stock

What is the CNMD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CONMED Corp. have a median 12-month price target of $45, with estimates ranging from $43 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNMD stock a buy right now?

Of the 7 analysts covering CONMED Corp., 0 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CONMED Corp. 95 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNMD?

As at 15 Aug 2026, CONMED Corp. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will CNMD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -10.7% from the last close, and Ticker Nerd's factor model ranks CONMED Corp. 95 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNMD stock forecast for 2030?

No analyst covering CONMED Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $49 over the next 12 months.

How has CNMD stock performed over the past year?

CONMED Corp. returned -3.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CONMED Corp. do?

CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical equipment and medical devices for orthopedic and general surgery specialties. The company's orthopedic surgery segment provides products for soft tissue repair, powered resection instruments, and foot and ankle surgery systems.

What is the latest news on CNMD?

The most recent item we track (Zacks Investment Research, 30 July 2026): "CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands". CONMED reported second-quarter earnings and revenues that surpassed analyst estimates, with expanding gross margins and strong international sales contributing to an improved earnings-per-share outlook for 2026.

Company

About CONMED Corp.

CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical equipment and medical devices for orthopedic and general surgery specialties. The company's orthopedic surgery segment provides products for soft tissue repair, powered resection instruments, and foot and ankle surgery systems. Its general surgery division offers advanced surgical and endoscopic technologies, including the AirSeal insufflation system for minimally invasive procedures, smoke evacuation products, electrosurgical generators, and specialized devices for gastroenterology and pulmonology procedures. CONMED serves healthcare professionals including surgeons and specialists in orthopedics, general surgery, gynecology, thoracic surgery, and related fields across approximately 100 countries. The company operates through sales subsidiaries and distribution networks in major markets including the United States, Europe, Asia Pacific, and other regions. CONMED caters to various healthcare settings ranging from ambulatory surgery centers and endoscopy suites to large hospital systems, focusing on delivering solutions that enhance surgical efficiency and patient outcomes in value-based care environments.

CEO Mr. Patrick J. Beyer · 3,900 employees · United States · https://www.conmed.com